The many clinical advantages of reporting the cycle threshold (Ct) value

Lippi, Giuseppe; Plebani, Mario

doi:10.21037/atm-22-1104

Cited by 6 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, measuring the viral load (either with SARS -CoV -2 molecular or antigen assays) may be advisable for defining the basic infectivity and predicting the clinical course of the disease, but also for anticipating the risk of long -term consequences after an acute SARS -CoV -2 infection. 26 June 20, 2022) with 17 256 654 participants, concluded that COVID -19 vaccination was globally associated with lower risks of long -COVID, with 2 vaccine doses displaying more favorable result than a single administration. Notably, out of 11 studies investigating the variation of long -COVID symptoms after vaccination, 7 concluded that long -COVID symptomatology may improve after COVID -19 vaccination.…”

Section: Impact Of Sars -Cov -2 Variantsmentioning

confidence: 99%

COVID-19 and its long-term sequelae: what do we know in 2023?

Lippi¹,

Sanchís-Gomar²,

Henry³

2023

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

vaccine -elicited, or both) or the virus attenuation, 3 the overall number of deaths and the mortality rate are also substantially underestimated. According to recent epidemiologic evidence from the WHO, the global number of COVID -19-related deaths may be up to 3 -fold higher than officially reported, 4 with ample variations in the volume of excess deaths worldwide (eg, the underestimation bias may even exceed 50% in certain South American regions). Likewise, a debate is fueling over the fact that the way COVID -19-related deaths are counted in some countries may not reflect the real scenario, with several million deaths missed by official statistics. 5 That said, and with the apparent preamble that pandemic numbers are largely biased and will continue to grow in the foreseeable future (COVID -19 seems now Current epidemiology of COVID -19 COVID -19 is a life -threatening infectious disease sustained by SARS -CoV -2, the virus first identified in the Chinese town of Wuhan in November 2019. Thereafter, it has spread rapidly worldwide, and the World Health Organization (WHO) has finally classified it as a pandemic disease in March 2020. 1 The accurate characterization of the ongoing COVID -19 epidemic is challenging for countless reasons. First, the number of official cases of SARS -CoV -2 infection is underestimated mainly because of under testing and under -reporting all around the world, making it impossible to provide accurate measures of its current frequency. 2 Then, although it is undeniable that the clinical severity of COVID -19 has considerably declined over time due to either immunity (natural,

show abstract

Section: Impact Of Sars -Cov -2 Variantsmentioning

confidence: 99%

COVID-19 and its long-term sequelae: what do we know in 2023?

Lippi¹,

Sanchís-Gomar²,

Henry³

2023

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…The assessment of viral load in subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is important, since this parameter has a considerable impact on the clinical decision making and on the managed care of patients with coronavirus disease 2019 (COVID-19), i.e., for defining the infective risk (and the consequent isolation period), for prognosticating disease progression, as well as for predicting the likelihood of developing long-COVID [1]. During the first period of the pandemic the nasopharyngeal viral load measured in COVID-19 patients did not display major age or sex differences.…”

Section: Introductionmentioning

confidence: 99%

Age and sex variation of SARS-CoV-2 cycle threshold value during prevalence of Omicron BA.5 sublineage

Pighi¹,

Henry²,

Nitto³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: In this work we explore the possibility that age and sex may have an impact on the nasopharyngeal viral load of subjects infected by the SARS-CoV-2 Omicron BA.5 sublineage. Methods: The study population was a cohort of outpatients who initially presented to the COVID-19 diagnostic facility of Hospital Pederzoli (Peschiera del Garda, Verona, Italy) ≤3 days from onset of suggestive symptoms, and subsequently tested positive for SARS-CoV-2. The study took place when the local prevalence of SARS-CoV-2 Omicron BA.5 sublineage was >90%. A nasopharyngeal swab was collected and immediately transported to the local diagnostic laboratory, where it was used for SARS-CoV-2 testing with Xpert Xpress SARS-CoV-2. Results: The final study population consisted in 112 subjects, with median age of 45 years (77 females). In univariate analysis, no significant correlation was found between Ct value and sex (r= 0.02; p=0.817) or age (r= 0.02; p=0.798). the mean Ct value did not differ between males (24.7; IQR, 21.7-29.3) and females (25.2; IQR, 21.1-30.4; p=0.389). In multivariate analysis, the mean Ct values was not associated with sex (p=0.779) or age (p=0.979). Conclusion: The viral load in patients with SARS-CoV-2 Omicron BA.5 infection is not dependent on age and sex.

show abstract

Ad interim recommendations for diagnosing SARS-CoV-2 infection by the IFCC SARS-CoV-2 variants working group

Lippi

Favresse

Gromiha

et al. 2022

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

This document, endorsed by the IFCC Working Group on SARS-CoV-2 Variants, aims to update previous indications for diagnosing acute SARS-CoV-2 infection, taking into consideration the evidence that has emerged after the origin and spread of new lineages and sub-lineages of the virus characterized by mutated genetics and altered biochemical, biological and clinical characteristics. These indications encompass the use of different diagnostic strategies in specific clinical settings, such as high risk of SARS-CoV-2 infection (symptomatic patients), low risk of SARS-CoV-2 infection (asymptomatic subjects) at hospital admission/contact tracing, testing in asymptomatic subjects, in epidemiologic surveys and/or population screening, along with tentative indications for identification of new lineages and/or sub-lineages of SARS-CoV-2.

show abstract

The many clinical advantages of reporting the cycle threshold (Ct) value

Cited by 6 publications

References 7 publications

COVID-19 and its long-term sequelae: what do we know in 2023?

COVID-19 and its long-term sequelae: what do we know in 2023?

Age and sex variation of SARS-CoV-2 cycle threshold value during prevalence of Omicron BA.5 sublineage

Ad interim recommendations for diagnosing SARS-CoV-2 infection by the IFCC SARS-CoV-2 variants working group

Contact Info

Product

Resources

About